Tfayli Arafat H, El-Halabi Laura N, Khuri Fadlo R
Naef K. Basile Cancer Institute, Division of Hematology/Oncology, American University of Beirut Medical Center, Beirut, Lebanon.
Cancer. 2025 Jan 1;131(1):e35590. doi: 10.1002/cncr.35590. Epub 2024 Nov 18.
Cancer remains a significant challenge for health care systems, despite notable progress in the field. These advancements have significant financial implications that disproportionately affect low-income countries. This review article aims to explore the present state of drug development, assessing the availability of drugs in different income countries, and proposing potential solutions to address the inequality in access to new cancer treatments.
A search was conducted on MEDLINE and PubMed on October 2, 2023 and updated on December 14, 2023, limited to English language articles.
There is a projected rise in cancer cases worldwide, particularly in low-income countries where most cancer-related deaths are expected. Although the approval rate of cancer treatments has risen, their excessive cost and lack of affordability pose significant barriers to widespread access. Disparities in the costs of crucial cancer medications are influenced by geographic location and procurement connections. Potential solutions to address the inequity in drug distribution include sharing production secrets, implementing price discrimination, international funding, improved primary health care measures, and the implementation of cost-effective screening methods.
Preventing, screening for, and treating cancer should be a global priority with minimal differences in access to therapy among various countries.
尽管癌症领域取得了显著进展,但癌症仍然是医疗保健系统面临的重大挑战。这些进展带来了巨大的经济影响,对低收入国家造成了不成比例的影响。这篇综述文章旨在探讨药物研发的现状,评估不同收入水平国家的药物可及性,并提出解决新癌症治疗可及性不平等问题的潜在解决方案。
于2023年10月2日在MEDLINE和PubMed上进行搜索,并于2023年12月14日更新,仅限于英文文章。
预计全球癌症病例将增加,尤其是在低收入国家,预计大多数与癌症相关的死亡将发生在这些国家。尽管癌症治疗的批准率有所提高,但其高昂的成本和可负担性不足对广泛可及性构成了重大障碍。关键癌症药物成本的差异受到地理位置和采购关系的影响。解决药物分配不平等问题的潜在解决方案包括分享生产秘密、实施价格歧视、国际资助、改善初级卫生保健措施以及实施具有成本效益的筛查方法。
预防、筛查和治疗癌症应成为全球优先事项,各国在治疗可及性方面的差异应最小化。